AKBA — Akebia Therapeutics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1517022 ·
Last close
$0.89
Market Cap
$247.48M
52W High
$3.20
52W Low
$0.81
ADV30
7,993,885
Next earnings
2026-11-09

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 49,128,000 38,704,000 -4,381,000 -8,908,000 349,658,000 155,548,000 324,640,000
Mar 2026 53,544,000 41,254,000 -4,696,000 -9,054,000 362,520,000 162,644,000 335,145,000
Dec 2025 57,622,000 45,087,000 -8,553,000 -12,244,000 376,565,000 184,844,000 343,955,000
Sep 2025 58,766,000 49,383,000 4,449,000 540,000 364,152,000 166,444,000 322,560,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$41,552,000
Investing CF
$-12,095,000
Financing CF
$-11,199,000
CapEx
$-12,095,000
Dividends Paid
—
Buybacks
$-63,000
EPS Diluted TTM
$-0.11
As of
2026-08-09

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,701,667,000
Inventory
$13,018,000
Receivables
$53,506,000
ST Investments
—
EBIT TTM
$-10,509,000
Pretax Income TTM
$-27,846,000
Interest Exp TTM
$17,337,000
Analysts
5

Yahoo Snapshot (yfinance, live)

Total Revenue
$219,060,000
EBITDA
$-4,296,000
Free Cash Flow
$33,636,376
Enterprise Value
$307,362,016
Total Cash
$155,548,000
Total Debt
$199,188,000
Shares Out
277,106,245
Trailing EPS
$-0.12
Book Value
$0.09
ROE
-109.4%
ROA
-1.1%
Div Yield
—

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 236,196,000 23,499,000 -5,345,000 376,565,000 343,955,000 32,610,000 67,992,000
Dec 2024 160,180,000 -50,414,000 -69,410,000 220,670,000 269,855,000 -49,185,000 -40,659,000
Dec 2023 194,623,000 -46,075,000 -51,925,000 241,703,000 272,287,000 -30,584,000 -23,384,000
Dec 2022 292,484,000 -64,846,000 -94,226,000 356,054,000 350,824,000 5,230,000 -73,154,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$94,764,000
NetIncome TTM
$-13,927,000
OpCashFlow TTM
$0
Assets (Latest)
$376,565,000
Forward EPS
$-0.36

Max Pain — expiry 2027-01-15

max pain strike: $1.50 · spot: $0.89 · call oi: 0 · put oi: 1,313
Expected Move to 2027-01-15: ±$0.38 (42.55%) — implied range $0.51 – $1.27 · ATM straddle on $1.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
LFCR LIFECORE BIOMEDICAL, INC. \DE\ $246.80M $6.52 —
SIGA SIGA TECHNOLOGIES INC $248.60M $3.46 —
ZNTL Zentalis Pharmaceuticals, Inc. $246.15M $2.60 —
TRDA Entrada Therapeutics, Inc. $242.19M $6.22 —
PYXS Pyxis Oncology, Inc. $241.88M $2.90 —

News headlines (Yahoo Finance, 1h cache)

Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases
2026-09-14 12:00 · Yahoo
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-01 20:05 · Yahoo
Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston
2026-09-01 12:00 · Yahoo
Akebia Therapeutics Inc (AKBA) (Q2 2026) Earnings Call Highlights: Vafseo Surges 60% as VOICE ...
2026-08-06 05:10 · Yahoo
Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates
2026-08-05 22:10 · Yahoo
Akebia Therapeutics Q2 Earnings Call Highlights
2026-08-05 22:03 · Yahoo
Akebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business Highlights
2026-07-29 12:00 · Yahoo
Akebia Therapeutics, Inc. (AKBA) Strengthens Vafseo Patent Protection Through 2036
2026-06-30 13:10 · Yahoo
Akebia Therapeutics Strengthens Vafseo® (vadadustat) Patent Portfolio
2026-06-10 12:00 · Yahoo
Akebia Therapeutics Sees Vafseo Uptake Rising as Access and Pipeline Milestones Near
2026-06-05 00:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.